Chronic low-grade systemic inflammation in patients with long-standing rheumatoid arthritis (RA) contributes beyond joint damage to metabolic dysregulation, endothelial dysfunction, and heightened cardiovascular risk. Combination disease-modifying antirheumatic drugs (DMARDs) remain central to RA management, but their long-term ability to fully suppress systemic inflammation and prevent metabolic complications is reported to be limited in longstanding disease. Phytochemicals such as resveratrol, a polyphenolic compound used in traditional and complementary medicine, have documented anti-inflammatory and immunomodulatory properties and were evaluated here as a potential adjunct to standard DMARD regimens.
The primary objective was to investigate whether resveratrol can complement the immunomodulatory effects of combination DMARDs in patients with long-duration RA by modulating inflammatory cytokines and the JNK–IRS–Akt insulin signaling axis. The study compared early and late RA cohorts to identify differences in inflammatory status and signaling and used ex vivo assays on isolated PBMCs to test direct effects of resveratrol on cellular viability, cytokine production, adipokine profiles, and kinase signaling.
Study subjects included patients with early and long-standing RA; clinical disease activity and vascular/atherosclerotic markers were measured longitudinally. Peripheral blood mononuclear cells (PBMCs) were isolated for ex vivo experiments. Cytotoxicity testing established that resveratrol preserved PBMC viability under the conditions used. PBMCs were then stimulated with lipopolysaccharide (LPS) to induce proinflammatory responses and treated with resveratrol. Downstream readouts included ELISA measurements of cytokines and adipokines and Western blot analysis of signaling proteins, focusing on phosphorylated JNK (pJNK), GSKβ, and Akt-related signaling components. Statistical comparisons were used to evaluate immunomodulatory effects and alterations in inflammatory signaling between early and late disease and in response to resveratrol treatment.
Longitudinal clinical follow-up documented significant improvement in disease activity and in measures of atherosclerotic risk during the first year, and these early improvements correlated with methotrexate dosing within the combination DMARD regimens. When early RA and longstanding RA groups were compared, the longstanding group displayed elevated circulating cytokine levels and enhanced JNK-mediated stress signaling, indicating persistent inflammatory and metabolic disturbance despite standard DMARD therapy.
In ex vivo PBMC assays, resveratrol did not reduce cell viability, supporting tolerability of the compound in the experimental system. Functionally, resveratrol reduced LPS-induced TNFα production and corrected adipokine imbalances observed in PBMC supernatants. On signaling assessment, resveratrol treatment downregulated phosphorylated JNK (pJNK) and GSKβ, consistent with selective inhibition of stress kinase pathways. These modulations were observed without concurrent activation of Akt, suggesting that resveratrol’s anti-inflammatory effects in this setting were mediated primarily through JNK pathway suppression rather than broad Akt pathway activation.
The authors report that long-standing RA is characterized by persistent inflammatory and metabolic dysregulation driven in part by JNK–NF-κB activation. In their ex vivo system, resveratrol reduced proinflammatory cytokines, corrected adipokine imbalance, and selectively inhibited JNK signaling while leaving Akt activation unchanged. These findings are interpreted to support potential adjunctive therapeutic value for resveratrol alongside combination DMARDs to improve immunometabolic disturbances in patients with longstanding RA.
It is important to note that this report is a preprint and has not been peer reviewed; the authors explicitly state the work should not be used to guide clinical practice until validated by further peer-reviewed studies.
The study authors declared that institutional ethics committee approval and written informed consent were obtained; the protocol was approved by the institutional ethics committee of the Institute of Post Graduate Medical Education & Research, Kolkata, and conducted according to ICMR Ethical Guidelines 2006. The authors declared no competing interests. Funding was declared from the Indian Council of Medical Research (ICMR), Government of India. The preprint indicates that all data produced in the work are contained within the manuscript and are available on reasonable request to the authors.
Note: The summary above is drawn from the preprint abstract and author declarations. Detailed numerical results, specific patient numbers, dosing regimens, statistical values, and full experimental protocols were not reported in the abstract and would need to be consulted in the full manuscript or supplementary materials for clinical or implementation decisions.